Keyphrases
Mouse Model
100%
Antiviral Response
100%
Hepatitis B Vaccine
100%
Hepatitis B e Antigen (HBeAg)
100%
Immunogenicity
100%
Hepatitis B Virus
70%
Vaccination
20%
Virus-specific
20%
Therapeutic Vaccination
20%
Hepatitis B Carrier
20%
Liver Damage
20%
C57BL
10%
Treatment Options
10%
Direct Transmission
10%
Mouse Liver
10%
Tolerability
10%
Effector Function
10%
CD8+ T Cells
10%
Particulate
10%
Hepatitis B Virus Replication
10%
Chronic Hepatitis B
10%
Immunization
10%
Antiviral Immunity
10%
Hepatitis B Surface Antigen (HBsAg)
10%
Specific Immune Response
10%
Chronic Hepatitis B Virus Infection
10%
Modified Vaccinia Virus Ankara
10%
Virus Genome
10%
Anti-hepatitis B Virus
10%
Natural Course
10%
Core Protein
10%
Cytolytic Activity
10%
Virus-neutralizing Antibody
10%
Fulminant Hepatitis B
10%
Overlength
10%
Precore Region
10%
Adeno-associated Viral Vector
10%
Non-haemolytic
10%
Novel Treatments
10%
Stop Codon mutation
10%
Pharmacology, Toxicology and Pharmaceutical Science
Immunogenicity
100%
Mouse Model
100%
Infection
100%
Antivirus Agent
100%
Hepatitis B Virus
100%
Hepatitis B(e) Antigen
81%
Liver Injury
18%
Chronic Hepatitis B
18%
Virus Carrier
18%
Tolerability
9%
C57BL 6 Mouse
9%
Modified Vaccinia Ankara
9%
CD8 Antigen
9%
Adeno Associated Virus Vector
9%
Hepatitis B
9%
Core Protein
9%
Hepatitis
9%
Hepatitis B Antigen
9%
Hepatitis B Vaccine
9%
Antibodies
9%
Immunology and Microbiology
Immunogenicity
100%
Mouse Model
100%
Hepatitis B Virus
100%
Hepatitis B(e) Antigen
81%
Hepatitis B
27%
Virus Carrier
18%
Viral Replication
9%
HBsAg
9%
Hepatitis B Vaccine
9%
Cytotoxic T-Cell
9%
Immune Response
9%
Virus Genome
9%
Adeno Associated Virus Vector
9%
Modified Vaccinia Ankara
9%
C57BL 6 Mouse
9%
Virus Immunity
9%
Stop Codon
9%
Hepatitis B Antigen
9%
Hepatitis
9%
Antibodies
9%